摘要
目的：了解我院2011-2013年抗肿瘤分子靶向药物的应用情况,为临床合理应用提供参考。方法：对我院2011-2013年抗肿瘤分子靶向药物应用品种、销售金额排序法、用药频度（DDDs）、限定日费用（DDC）等进行回顾分析。结果：我院抗肿瘤分子靶向药物占全院肿瘤用药的比例逐年增加,2012年、2013年构成比超过60%,其中蛋白激酶抑制药（TKI）占肿瘤靶向药物总金额的41.29%-73.41%,单克隆抗体（Mab）构成比19.40%-30.88%,其他药物构成比7.19%-27.83%。利妥昔单抗、西妥昔单抗的消耗金额与用药人次同步性不好,患者承担费用较高。结论：我院抗肿瘤分子靶向药物呈逐年增加趋势,其中尤以口服靶向药物应用更为广泛。
Objective： To invetigate the use of targeted anticancer drugs in our hospital during 2011-2013 to provide reference for the clinical rational drug use. Methods： The utilization of anti-tumor molecular targeted drugs in our hospital during 2011-2013 was retrospectively analyzed in respect of consumption sum, DDDs and DDC. Results： The proportion of consmption sum of anti-tumor mo- lecular targeted drugs in the total consumption sum was increased year by year, and that in 2012 and 2013 was over 60%. Prutease ki- nase inhibitors accounted for 41.29%-73.41% in the consumption sum of anti-tumor molecular targeted drugs; monoclonal antibody accounted for 19.40% -30.88% ; the other drugs accounted for 7.19% -27.83%. The consumption sum and the number of receiving medication patients of rituxan and cetuximab were not synchronized well, and the patients were born the higher cost. Conclusion： The use of anti-tumor molecular targeted drugs in our hospital is increased year by year, and the oral administration of anti-tumor molecular targeted drugs is with especially wide application.
出处
《中国药师》
CAS
2015年第6期981-984,共4页
China Pharmacist
